Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

QXQingyu XuTSTing ShiWGWen Gao

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows G-CSF combined with venetoclax and azacitidine improves responses in higher-risk MDS, suggesting effective treatment strategy.

Key Points

  • Complete remission observed in over 70% of higher-risk MDS patients after VAG regimen, highlighting treatment effectiveness.
  • The overall response rate reached 88%, with significant reductions in transfusion dependence noted in the cohort.
  • Analysis involved a consistent application of a 14-day venetoclax and 7-day azacitidine combined with G-CSF regimen.
  • High rates of adverse events were reported, predominantly involving neutropenia and anemia, indicating need for monitoring.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d897https://doi.org/10.1182/blood-2025-5646
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia2025
  2. 2A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  3. 3Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)2025
  4. 4Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  5. 5Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026